Axon Enterprise (AXON) beat expectations in FY2026 on revenue of $40.0B versus the $38.5B estimate (+19.3% YoY) and EPS of $2.97. Below is the full Axon Enterprise earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
$40.0B (vs $38.5B est · +4.0% surprise · +19.3% YoY)
EPS
$2.97 (vs $2.83 est · +4.9% surprise · +8.5% YoY)
Share price
$132.40 (-0.5%)
Market cap
$1.87T
What you'll find
Next Axon Enterprise (AXON) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Axon Enterprise reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Axon Enterprise (AXON)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Axon Enterprise's next earnings date?
Magnisto tracks Axon Enterprise's (AXON) earnings schedule and shows the confirmed next earnings date, the options-implied expected move and the estimates analysts are modeling into the print.
Did Axon Enterprise (AXON) beat or miss earnings?
In FY2026, Axon Enterprise (AXON) posted beat results — revenue of $40.0B versus the $38.5B estimate (+4.0% surprise) and EPS of $2.97 versus $2.83 expected (+4.9% surprise). Magnisto decodes every Axon Enterprise (AXON) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Axon Enterprise (AXON) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Axon Enterprise (AXON), anchored to the current $132.40 share price, so you can weigh the bull, base and bear cases for Axon Enterprise side by side.
Is Axon Enterprise (AXON) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Axon Enterprise fits your own thesis and risk profile. This is research, not investment advice.